Rare Presentation of Cardiotoxicity Related to 5-Fluorouracil

被引:3
作者
Charkviani, Mariam [1 ]
Murvelashvili, Natia [1 ]
Barrera, Francisco [1 ]
Sharma, Alisha [1 ]
Eldin, Randa Sharag [1 ]
Nabil, Nur Un Nisa [1 ]
机构
[1] Amita St Francis Hosp, Evanston, IL 60202 USA
关键词
SYMPTOMATIC CARDIOTOXICITY; CAPECITABINE; CHEMOTHERAPY; INFUSION;
D O I
10.1155/2020/4151474
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
5-Fluorouracil (5-FU) is a chemotherapeutic agent frequently used for the treatment of solid tumors. In a few cases, 5-FU can be associated with coronary vasospasm, cardiac ischemia, or life-threatening arrhythmias. Recognition of 5-FU cardiotoxicity is clinically important as after the rapid sensation of therapy, cardiotoxicity can be completely reversible, and on the other hand, readministration may lead to serious damage of the heart and even death. A 70-year-old male came to the emergency department (ED) with chest pain which started while receiving an infusion of 5-FU. The patient did not have a personal history or risk factors of coronary artery disease and his electrocardiogram (ECG) before starting chemotherapy was completely normal. In the ED, his ECG had ischemic changes, troponin was elevated, and echocardiogram showed anterior wall hypokinesis. However, emergent coronary angiogram did not reveal any acute coronary occlusion. 5-FU-induced cardiotoxicity was suspected; the patient was admitted to a progressive care unit for close monitoring and infusion of calcium channel blockers was initiated. The patient's symptoms and ECG findings gradually resolved, and two days later on discharge, patient was chest pain free and ECG was normal. This case supports the vasospastic hypothesis of 5-FU cardiac toxicity, describes its clinical course, and emphasizes the importance of better awareness and early recognition of the rare side effect as it may allow physicians to reduce the risk of life-threatening complications.
引用
收藏
页数:4
相关论文
共 16 条
  • [1] AKHTAR SS, 1993, ONCOLOGY, V50, P441
  • [2] Uridine triacetate for severe 5-fluorouracil toxicity in a patient with thymidylate synthase gene variation: Potential pharmacogenomic implications
    Baldeo, Candice
    Vishnu, Prakash
    Mody, Kabir
    Kasi, Pashtoon Murtaza
    [J]. SAGE OPEN MEDICAL CASE REPORTS, 2018, 6
  • [3] Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: Results of a phase III randomized trial of the European organization for research and treatment of cancer radiotherapy and gastrointestinal cooperative groups
    Bartelink, H
    Roelofsen, F
    Eschwege, F
    Rougier, P
    Bosset, JF
    Gonzalez, DG
    Peiffert, D
    vanGlabbeke, M
    Pierart, M
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1997, 15 (05) : 2040 - 2049
  • [4] Fluoropyrimidine-induced cardiac toxicity: challenging the current paradigm
    Clasen, Suparna C.
    Ky, Bonnie
    O'Quinn, Rupal
    Giantonio, Bruce
    Teitelbaum, Ursina
    Carver, Joseph R.
    [J]. JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2017, 8 (06) : 970 - 979
  • [5] CURTIN NJ, 1991, CANCER RES, V51, P2346
  • [6] CARDIOTOXICITY OF HIGH-DOSE CONTINUOUS INFUSION FLUOROURACIL - A PROSPECTIVE CLINICAL-STUDY
    DEFORNI, M
    MALETMARTINO, MC
    JAILLAIS, P
    SHUBINSKI, RE
    BACHAUD, JM
    LEMAIRE, L
    CANAL, P
    CHEVREAU, C
    CARRIE, D
    SOULIE, P
    ROCHE, H
    BOUDJEMA, B
    MIHURA, J
    MARTINO, R
    BERNADET, P
    BUGAT, R
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (11) : 1795 - 1801
  • [7] Cardiotoxicity of fluoropyrimidines in different schedules of administration: a prospective study
    Kosmas, Christos
    Kallistratos, Manolis S.
    Kopterides, Petros
    Syrios, John
    Skopelitis, Helias
    Mylonakis, Nicolaos
    Karabelis, Athanasios
    Tsavaris, Nicolas
    [J]. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (01) : 75 - 82
  • [8] Meyer CC, 1997, PHARMACOTHERAPY, V17, P729
  • [9] MOSSERI M, 1993, CANCER RES, V53, P3028
  • [10] The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC)
    Ng, M
    Cunningham, D
    Norman, AR
    [J]. EUROPEAN JOURNAL OF CANCER, 2005, 41 (11) : 1542 - 1546